These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33859643)
1. Ganglioside GD3 May Suppress the Functional Activities of Benign Skin T Cells in Cutaneous T-Cell Lymphoma. Kume M; Kiyohara E; Matsumura Y; Koguchi-Yoshioka H; Tanemura A; Hanaoka Y; Taminato M; Tashima H; Tomita K; Kubo T; Watanabe R; Fujimoto M Front Immunol; 2021; 12():651048. PubMed ID: 33859643 [TBL] [Abstract][Full Text] [Related]
2. Malignant and Benign T Cells Constituting Cutaneous T-Cell Lymphoma. Nakai S; Kiyohara E; Watanabe R Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884736 [TBL] [Abstract][Full Text] [Related]
3. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. Wolk K; Mitsui H; Witte K; Gellrich S; Gulati N; Humme D; Witte E; Gonsior M; Beyer M; Kadin ME; Volk HD; Krueger JG; Sterry W; Sabat R Clin Cancer Res; 2014 Nov; 20(21):5507-16. PubMed ID: 25212608 [TBL] [Abstract][Full Text] [Related]
4. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Guenova E; Watanabe R; Teague JE; Desimone JA; Jiang Y; Dowlatshahi M; Schlapbach C; Schaekel K; Rook AH; Tawa M; Fisher DC; Kupper TS; Clark RA Clin Cancer Res; 2013 Jul; 19(14):3755-63. PubMed ID: 23785046 [TBL] [Abstract][Full Text] [Related]
5. High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma. Clark RA; Shackelton JB; Watanabe R; Calarese A; Yamanaka K; Campbell JJ; Teague JE; Kuo HP; Hijnen D; Kupper TS Blood; 2011 Feb; 117(6):1966-76. PubMed ID: 21148332 [TBL] [Abstract][Full Text] [Related]
6. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Edelson RL Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563 [TBL] [Abstract][Full Text] [Related]
7. Expression of the Voltage-Gated Potassium Channel Kv1.3 in Lesional Skin from Patients with Cutaneous T-Cell Lymphoma and Benign Dermatitis. Hu T; Krejsgaard T; Nastasi C; Buus TB; Nansen A; Hald A; Spee P; Nielsen PR; Blümel E; Gluud M; Willerslev-Olsen A; Woetmann A; Bzorek M; Eriksen JO; Ødum N; Rahbek Gjerdrum LM Dermatology; 2020; 236(2):123-132. PubMed ID: 31536992 [TBL] [Abstract][Full Text] [Related]
8. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174 [TBL] [Abstract][Full Text] [Related]
9. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574 [TBL] [Abstract][Full Text] [Related]
10. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782 [TBL] [Abstract][Full Text] [Related]
11. Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. Rea B; Haun P; Emerson R; Vignali M; Farooqi M; Samimi S; Elenitsas R; Kirsch I; Bagg A J Clin Pathol; 2018 Sep; 71(9):814-820. PubMed ID: 29636372 [TBL] [Abstract][Full Text] [Related]
12. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Rook AH; Gelfand JM; Wysocka M; Troxel AB; Benoit B; Surber C; Elenitsas R; Buchanan MA; Leahy DS; Watanabe R; Kirsch IR; Kim EJ; Clark RA Blood; 2015 Sep; 126(12):1452-61. PubMed ID: 26228486 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. Nagatani T; Miyazawa M; Matsuzaki T; Iemoto G; Kim ST; Baba N; Miyamoto H; Nakajima H Semin Dermatol; 1994 Sep; 13(3):216-22. PubMed ID: 7986691 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous manifestations of Epstein-Barr virus-associated T-cell lymphoma. Su IJ; Tsai TF; Cheng AL; Chen CC J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):685-92. PubMed ID: 8227539 [TBL] [Abstract][Full Text] [Related]
15. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70. Ferenczi K; Ohtola J; Aubert P; Kessler M; Sugiyama H; Somani AK; Gilliam AC; Chen JZ; Yeh I; Matsuyama S; McCormick TS; Cooper KD Br J Dermatol; 2010 Sep; 163(3):564-71. PubMed ID: 20408834 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Delfau-Larue MH; Laroche L; Wechsler J; Lepage E; Lahet C; Asso-Bonnet M; Bagot M; Farcet JP Blood; 2000 Nov; 96(9):2987-92. PubMed ID: 11049975 [TBL] [Abstract][Full Text] [Related]
17. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21. Wang Y; Gu X; Li W; Zhang Q; Zhang C J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600 [TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969 [TBL] [Abstract][Full Text] [Related]